On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their August 2023 meeting. Actions in this consultation include:
- Sodium chloride 5% eye drops – RED
- Bempedoic acid – comments sought regarding a change to GREEN
- Steroid eye drops (betamethasone 0.1%, dexamethasone 0.1%, prednisolone 0.03%, 0.1%, 0.5% & 1%, fluorometholone 0.1%) – GREEN (specialist initiation)
- Rimegepant for preventing migraine – GREEN (specialist initiation) OR GREEN (specialist advice)
- Semaglutide for overweight and obesity in young people aged 12-17 years – Do Not Prescribe.
All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.
The consultation will run for six weeks and closes at 5pm on Friday 22nd September 2023. To take part, visit the consultations page.